2cdd: Difference between revisions

From Proteopedia
Jump to navigationJump to search
OCA (talk | contribs)
No edit summary
OCA (talk | contribs)
No edit summary
Line 4: Line 4:


==Overview==
==Overview==
Hsp90 encodes a ubiquitous molecular chaperone protein conserved among, species which acts on multiple substrates, many of which are important, cell-signaling proteins. Inhibition of Hsp90 function has been promoted as, a mechanism to degrade client proteins involved in tumorigenesis and, disease progression. Several assays to monitor inhibition of Hsp90, function currently exist but are limited in their use for a drug discovery, campaign. Using data from the crystal structure of an initial hit, compound, we have developed a fluorescence polarization assay to monitor, binding of compounds to the ATP-binding site of Hsp90. This assay is very, robust (Z' > 0.9) and can detect affinity of compounds with IC50s to 40, nM. We have used this assay in conjunction with cocrystal structures of, small molecules to drive a structure-based design program aimed at the, discovery and optimization of a novel class of potent Hsp90 inhibitors.
Hsp90 encodes a ubiquitous molecular chaperone protein conserved among species which acts on multiple substrates, many of which are important cell-signaling proteins. Inhibition of Hsp90 function has been promoted as a mechanism to degrade client proteins involved in tumorigenesis and disease progression. Several assays to monitor inhibition of Hsp90 function currently exist but are limited in their use for a drug discovery campaign. Using data from the crystal structure of an initial hit compound, we have developed a fluorescence polarization assay to monitor binding of compounds to the ATP-binding site of Hsp90. This assay is very robust (Z' > 0.9) and can detect affinity of compounds with IC50s to 40 nM. We have used this assay in conjunction with cocrystal structures of small molecules to drive a structure-based design program aimed at the discovery and optimization of a novel class of potent Hsp90 inhibitors.


==About this Structure==
==About this Structure==
Line 14: Line 14:
[[Category: Single protein]]
[[Category: Single protein]]
[[Category: Barril, X.]]
[[Category: Barril, X.]]
[[Category: Cheung, K.M.]]
[[Category: Cheung, K M.]]
[[Category: Drysdale, M.J.]]
[[Category: Drysdale, M J.]]
[[Category: Dymock, B.W.]]
[[Category: Dymock, B W.]]
[[Category: Grant, K.]]
[[Category: Grant, K.]]
[[Category: Howes, R.]]
[[Category: Howes, R.]]
Line 22: Line 22:
[[Category: Matthews, T.]]
[[Category: Matthews, T.]]
[[Category: Mcdonald, E.]]
[[Category: Mcdonald, E.]]
[[Category: Northfield, C.J.]]
[[Category: Northfield, C J.]]
[[Category: Robertson, A.]]
[[Category: Robertson, A.]]
[[Category: Surgenor, A.]]
[[Category: Surgenor, A.]]
Line 38: Line 38:
[[Category: pyrazole]]
[[Category: pyrazole]]


''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun Feb 3 10:34:09 2008''
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 16:47:29 2008''